E.mbrace - Extraintestinal e.Coli Infection

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years.

Principal Investigator: Christopher Pugh, DO

Sponsor: Janssen

Learn more about the E.mbrace trial or call the Clinical Trials Office at 484-628-8585 for more information.